^
    Back
    Association details:
    Biomarker:TP53 mutation + KRAS mutation
    Cancer:Lung Adenocarcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Pathol
    Title:

    Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy

    Published date:
    11/21/2022
    Excerpt:
    ...concomitant TP53 and KRAS mutations predicted a better PFS (p=0.015) and OS (p=0.029) compared with no mutations or a single mutation in either TP53 or KRAS.
    DOI:
    http://dx.doi.org/10.1136/jcp-2022-208574